The Real Reason You Age (And How to Slow It Down) | Dr. Eric Verdin & Dr. Mark Hyman
Why It Matters
Shifting focus from disease treatment to biological‑age reduction could dramatically extend healthspan, reshaping healthcare economics and patient outcomes.
Key Takeaways
- •Targeting biological aging could outweigh cholesterol in disease risk.
- •Inflammaging links mitochondria dysfunction to chronic disease progression.
- •Mitopure (Urolithin A) supports mitochondrial renewal, boosting vitality.
- •Functional medicine emphasizes root‑cause, not “whack‑a‑mole,” treatment approach.
- •Extending healthspan may add 30‑40 years versus treating individual diseases.
Summary
In a recent conversation, Dr. Eric Verdin of the Buck Institute and functional‑medicine physician Dr. Mark Hyman explore how science is moving from treating isolated diseases to modifying biological age itself.
They argue that aging is the dominant risk factor for heart disease, cancer, diabetes, Alzheimer’s and more, and that a person’s biological age now matters far more than cholesterol levels. The discussion references the “geoscience hypothesis” and the hallmarks of aging, especially chronic inflammation—or “inflammaging”—and mitochondrial decline.
Verdin describes current medicine as “whack‑a‑mole” care, while Hyman cites research suggesting that targeting aging could add 30‑40 healthy years, compared with only five to seven years from curing individual diseases. Both highlight emerging interventions, from gene‑editing to practical supplements like Mitopure (Urolithin A) that rejuvenate mitochondria.
If the paradigm shift succeeds, clinicians will focus on root‑cause strategies, insurers may cover anti‑aging therapies, and biotech firms stand to profit from a market that promises longer healthspans rather than merely longer lifespans.
Comments
Want to join the conversation?
Loading comments...